Rhumbline Advisers Has $303,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Rhumbline Advisers raised its holdings in Perspective Therapeutics, Inc. (NYSE:CATX) by 4.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 94,992 shares of the company’s stock after acquiring an additional 4,075 shares during the quarter. Rhumbline Advisers owned about 0.14% of Perspective Therapeutics worth $303,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. US Bancorp DE increased its holdings in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $153,000. WealthPlan Investment Management LLC bought a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $4,530,000. Victory Capital Management Inc. lifted its stake in shares of Perspective Therapeutics by 328.7% in the third quarter. Victory Capital Management Inc. now owns 50,460 shares of the company’s stock worth $674,000 after buying an additional 38,690 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $259,000. 54.66% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CATX has been the topic of a number of recent analyst reports. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Oppenheimer reduced their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Friday, January 24th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $15.13.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $2.61 on Monday. Perspective Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $19.05. The stock’s 50 day moving average price is $3.21 and its two-hundred day moving average price is $7.66.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.